Skip to main content
. 2018 Jan 11;23(2):16-00780. doi: 10.2807/1560-7917.ES.2018.23.2.16-00780

Table 4. Influenza vaccine effectiveness in preventing laboratory-confirmed cases by healthcare setting, age group and virus (sub)type, northern Spain, 2010/11 to 2015/16.

Age 50–64 years Age ≥ 65 years
All patients Outpatients Inpatients All patients Outpatients Inpatients
Influenza A(H1N1)pdm09
Cases, n (% vaccinated) 273 (15) 148 (12) 125 (19) 227 (55) 48 (56) 179 (55)
Controls, n (% vaccinated) 523 (27) 242 (20) 281 (32) 1,118 (66) 131 (55) 987 (67)
Crude VE, % (95% CI) 51 (28 to 67) 49 (7 to 72) 50 (16 to 70) 36 (15 to 52) –1 (–95 to 48) 40 (18 to 57)
Adjusted VE, % (95% CI) a 56 (31 to 72) 63 (26 to 82) 47 (2 to 72) 25 (–6 to 46) –20 (–200 to 52) 31 (1 to 52)
Influenza A(H3N2)
Cases, n (% vaccinated) 175 (17) 138 (15) 37 (24) 299 (62) 90 (59) 209 (63)
Controls, n (% vaccinated) 523 (27) 242 (20) 281 (32) 1118 (66) 131 (55) 987 (67)
Crude VE, % (95% CI) 43 (11 to 63) 31 (–24 to 60) 32 (–51 to 69) 16 (–10 to 35) –17 (–102 to 32) 17 (–14 to 39)
Adjusted VE, % (95% CI) a 36 (–12 to 63) 40 (–23 to 70) 39 (–71 to 78) 14 (–19 to 38) –48 (–249 to 38) 21 (–12 to 45)
Influenza B
Cases, n (% vaccinated) 124 (15) 98 (12) 26 (23) 140 (55) 36 (44) 104 (59)
Controls, n (% vaccinated) 523 (27) 242 (20) 281 (32) 1118 (66) 131 (55) 987 (67)
Crude VE, % (95% CI) 53 (20 to 73) 45 (–9 to 72) 36 (–64 to 75) 37 (9 to 55) 34 (–38 to 69) 31 (–4 to 54)
Adjusted VE, % (95% CI) a 47 (–2 to 73) 55 (–9 to 81) 13 (–184 to 73) 41 (10 to 61) 62 (–7 to 87) 40 (3 to 63)

CI: confidence interval; VE: vaccine effectiveness.

a Vaccine effectiveness adjusted by age groups 50–59, 60–69, 70–79 and ≥ 80 years), sex, major chronic conditions, functional dependence, hospitalisation in the previous 12 months, healthcare setting (primary healthcare and hospital), and influenza season and month of sample collection.